Background: Radiation therapy might modify the cancer immune environment to enhance the antitumor effect of immune checkpoint inhibitors. We performed a feasibility study of nivolumab following stereotactic radiation therapy for chemotherapy pretreated advanced non-small-cell lung cancer.
Introduction
Non-small-cell lung cancer (NSCLC) is a major cause of death worldwide. NSCLC accounts for 80-85% of all cases of lung cancer, and it is primarily treated with chemotherapy because numerous patients develop distant metastasis at the time of diagnosis or are ineligible for concurrent chemoradiotherapy. The previous development of therapeutics for NSCLC has mainly focused on molecular-targeted drugs for genetic alterations, such as epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase. In recent years, immuno-checkpoint inhibitors (ICIs) have attracted attention.
Negative signals transmitted to T cells through the interaction between programmed cell death 1 (PD-1) on T cells and programmed death-ligand 1 (PD-L1) on tumor cells suppress the activation of immune responses. Nivolumab, a PD-1 antibody, exerts an antitumor effect by inhibiting this interaction. Nivolumab prolonged the survival of NSCLC patients compared with docetaxel, the standard conventional second-line therapy for NLCLC (1, 2) . However, the response rate (20%) and median progression-free survival (2-4 months) were not satisfactory Radiation therapy is thought to modulate various immunoregulatory functions of tumor cells and enhance the efficacy of ICIs. The 1-year administration of durvalumab, a PD-L1 antibody, to patients with Stage III NSCLC after concurrent chemoradiotherapy significantly prolonged progression-free survival compared with placebo (3). However, few clinical data are available regarding the administration of ICIs after radiation therapy for advanced/recurrent NSCLC.
In this study, we attempted to investigate the safety of nivolumab administration after stereotactic radiation therapy (SRT) in chemotherapy pretreated patients with advanced/recurrent NSCLC.
Patients and methods
This study was a single-center feasibility study targeting chemotherapy pretreated patients with NSCLC. It was approved by the ethical review board of the Japanese Red Cross Medical Center, and written informed consent was obtained from all patients.
Patients
Eligible patients had histologically or cytologically confirmed NSCLC, were at least 20 years old and had Eastern Cooperative Oncology Group performance status of 0-2, SRT-treatable lesions outside the brain and bone, history of prior chemotherapies and adequate organ function (leukocyte count ≥3000/mm 3 , absolute neutrophil count ≥1500/mm 3 , platelet count ≥100 000/mm 3 , hemoglobin ≥9.0 g/dl, serum aspartate aminotransferase [AST] ≤100 IU/l, alanine aminotransferase [ALT] ≤100 IU/l, total bilirubin ≤1.5 mg/ dl and serum creatinine ≤1.5 mg/dl). The exclusion criteria included prior treatment with immune-stimulatory antitumor agents including checkpoint-targeted agents, being treated with an immunosuppressant (such as corticosteroids) regardless of reason, developing symptomatic brain metastasis, having an active autoimmune disease that could be exacerbated by the administration of an immunostimulant, interstitial pneumonia, active infectious disease, massive pleural, pericardial, or abdominal effusion or a severe co-morbidity such as heart disease, interstitial lung disease, inadequately controlled hypertension and diabetes mellitus.
Study design and treatment
The patients received 3 mg/kg of nivolumab within 2 weeks after the completion of SRT. If unacceptable toxicities were noted in three out of six cases, the study was discontinued. Unacceptable toxicities were defined as (i) Grade ≥3 pneumonitis and (ii) Grade ≥3 nonhematological toxicities (excluding nausea, vomiting, anorexia, constipation, electrolyte abnormality, ALP elevation and hyperglycemia) Abbreviations: ad, adenocarcinoma; NOS, not otherwise specified; amp, amplification; IHC, immunohistochemistry; TPS, tumor proportion score; GTV, gross tumor volume; PFS, progression-free survival.
*Tumors continued to response to nivolumab.
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according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. The observation period for unacceptable toxicities was set as 12 weeks for pneumonitis and 8 weeks for other toxicities. Treatment continued until radiographic disease progression, unacceptable toxicities, withdrawal from study or death. Treatment beyond progression was allowed. SRT was performed on the primary lesion or metastatic lesions except brain and bone metastases using the CyberKnife ® (CK) system (Accuray Incorporated, Sunnyvale, CA, USA). Additionally, SRT was planned to be done on the primary lesion preferably, but when it could not be done for some reason, metastatic lesions were selected instead. Thoracic SRT was performed with a setting such that the volume of normal lungs receiving ≥20 Gy irradiation (V20) did not exceed 30%. Dose limit for each organ was set based on Timmerman's review (4). Total radiation dose and dose per fraction were not explicitly predefined, but they were determined according to a patient's condition and the irradiation site after consultation with a radiotherapist. For example, SRT was performed at a lower dose for the central lung than that used for the peripheral lung considering severe adverse events. In addition, when the tumor size was large, the target volume was set within the gross tumor volume for safety.
The primary endpoint of this study was safety and the secondary, exploratory endpoint was response rate (RR) according to the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, including the target lesions both inside and outside the irradiated field.
Results

Patient characteristics
This study was conducted from September 2016 to September 2017 at the Japanese Red Cross Medical Center. Six patients with advanced NSCLC were enrolled. The patient baseline characteristics are shown in Table 1 . Two patients were current smokers and two patients were former smokers. Four patients underwent second-line therapy while two patients underwent third-line therapy. Four patients had a tumor proportion score of ≥50% by PD-L1 immunohistochemistry 22C3. Two patients had mutations in an EGFR gene (exon 20 insertion, exon 21 L858R) and one patient each had a KRAS gene mutation (G12C), MET amplification, or FGFR1 amplification. Four patients had measurable lesions outside the irradiated area, which included pleural nodules, adrenal grand and mediastinal lymph nodes.
Efficacy and toxicity
SRT to the primary lung lesion was performed in five cases. One patient (Patient 2) had previously undergone concurrent chemoradiotherapy and, therefore, received SRT to the cervical lymph nodes (Fig. 1) . Patients who underwent radiation to the primary lesions received a total dose of 25-48 Gy, which was divided into 3-4 fractions. All patients completed SRT and received nivolumab on the following day.
One unacceptable toxicity occurred in Patient 3, who developed Grade 3 pneumonitis after 5 cycles of nivolumab. Oxygen administration and hospitalization were required. However, symptoms and pneumonitis improved after the administration of oral prednisolone at an initial dose of 50 mg/day, which was successfully tapered and stopped after 2 months (Fig. 2) . This patient developed brain metastasis~6 months after nivolumab treatment and became progressive disease.
No other patients exhibited any unacceptable toxicities. Adverse events noted throughout the entire study period were generally mild, and no other serious hematological toxicities or immune-related adverse events were observed ( Table 2 ).
The median number of treatment cycles was 8 (range: 4-19), and a complete response (CR) and two partial responses (PR) were achieved. One patient exhibited clear disease progression within the non-irradiated field. Three of the four patients who had measurable lesions outside the irradiated area responded to nivolumab. Of the patients in whom CR and PR were achieved, all showed a high expression of PD-L1. The median progression-free survival was 4.6 months. The initial progression sites were pleural dissemination (patients 1 and 4), brain (patient 3), contralateral lobes (patient 5) and liver (patient 6).
Discussion
Radiation therapy is thought to modulate various immunoregulatory functions of tumor cells and enhance the efficacy of ICIs. The underlying mechanisms include an increased release of tumor antigens, enhanced invasion of CD8-positive T cells by tumor cells and increased PD-L1 expression rate in tumor cells (5, 6) . In addition, radiation therapy rarely acts on the tumor microenvironment outside the irradiation range to enhance immune responses, which might produce an abscopal effect (7) .
Since an adequate amount of tumor antigens would be released by irradiation to the pulmonary primary lesion, which usually has the largest tumor bulk, we supposed that SRT to the pulmonary region would be most effective. A prospective study about SRT followed by ICI has shown that toxicity mainly appeared in the irradiated region (8) . In this study, Grade 3 pneumonitis occurred in 20% of the cases with central lung lesions and 8.3% of those with the peripheral lung lesions. Thus, the authors concluded that the application of this therapy to central lung lesions should be performed with particular care. Since we were also concerned about an increased incidence of drug-or radiation-induced pneumonitis, the dose of irradiation to the central lung lesion was decreased tõ 30 Gy. In our study, five of the six patients received SRT to their primary lung lesions as we planned. As a result, only one patient developed significant pneumonitis, but no other serious adverse events were noted in all cycles. In our study, since SRT was not performed on other visceral lesions, the safety for other metastasis sites could not be clarified. However, several previous studies have reported acceptable tolerance (8, 9) . When the tumor size is large, it is also conceivable that more adverse events may occur due to the larger irradiation dose to the surrounding tissue. Therefore, we set the target volume only within the gross tumor volume (Patient 5). The aim of SRT was primarily to facilitate the release of tumor antigens and tumor invasion by T cells. Presumably, irradiation would be effective in only a part of a large tumor owing to the size as opposed to irradiation to the whole tumor, which is possible for small tumors. Although the criteria for changing the target volume according to the tumor size are unclear, Al-Hallaq et al. reported a criterion of a long diameter of 65 ml or <5 cm (10) .
A retrospective analysis indicated that the effects of ICIs can be expected in patients with a history of radiation therapy compared with those without a history of radiation therapy (11) . However, no clear data are available on the appropriate radiation site and radiation dose for enhancing the efficacy of immunotherapy, and the irradiation site and dose were not predetermined in our study. However, because efficacy was not observed in the previous study where an ICI was administered after radiation therapy in patients with bone metastasis of prostate cancer, bone metastases were excluded in our study (12) . Brain metastases were also excluded, because the effectiveness of ICI on brain metastases is controversial (13) . However, while some reports have indicated that severe edema was observed in patients who underwent sequential combination therapy with SRT and ICI for brain metastasis (14, 15) , other reports have described the usefulness of this therapy (16) . In addition, NSCLC frequently metastasizes to the brain. Therefore, this combination with SRT and ICIs for brain metastasis may be considered.
In the PEMBRO-RT study (NCT02492568), PFS and overall survival in the group of patients who underwent SRT were longer than those in the group of patients who did not (17) . In addition, no obvious increase in toxicity was observed even when SRT was added. In this study, the irradiation site was not specified. It is noteworthy that the irradiation dose was fixed to 3 × 8 Gy; because the biological effective dose was reduced, safe irradiation was possible regardless of the irradiation site. This may suggest that SRT had a strong effect on the immune environment of tumors. In our study, some patients underwent treatment with a curative dose. However, we are considering using a fixed dose with reduced biological effectiveness in future studies. The duration of the effect of radiation therapy on immune responses remains unclear. In a mammalian model, PD-L1 expression was reported to peak at 12-36 h after irradiation and then decline (18) . A subgroup analysis of the PACIFIC trial showed that the effect was enhanced in the group receiving durvalumab within 2 weeks after radiation therapy (3) . Therefore, to enhance the efficacy of radiation, nivolumab should be administered immediately after radiation therapy. Furthermore, concurrent therapy with SRT and ICIs is being investigated and tolerance appears to be generally good (19) . The sample size in our study was too small to make a firm conclusion, but acute toxicity did not increase even though nivolumab was administered the day after SRT was completed.
Conclusion
The relatively safe early administration of nivolumab was achieved after SRT. More data needs to be gathered through randomized clinical trials based on predetermined doses and fractions to further evaluate effects of SRT and ICIs.
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